Drug Repositioning for Preeclampsia Therapeutics by In Vitro Screening: Phosphodiesterase-5 Inhibitor Vardenafil Restores Endothelial Dysfunction via Induction of Placental Growth Factor

• Material Type: 記事
• Title: Drug Repositioning for Preeclampsia Therapeutics by In Vitro Screening: Phosphodiesterase-5 Inhibitor Vardenafil Restores Endothelial Dysfunction via Induction of Placental Growth Factor
• Author Heading: Aiko Kakigano; Takuji Tomimatsu; Kazuya Mimura; Tomoko Kanayama; Satoko Fujita; Kenji Minato; Keiichi Kumasawa; Yukiko Taniguchi; Takeshi Kanagawa; Masayuki Endo; https://ci.nii.ac.jp/author/DA19618585; Tomoaki Ishihara; Takushi Namba; https://orcid.org/0000-0003-4106-541X; Tohru Mizushima; Tadashi Kimura
• Publication Date: 2015-10
• Publication Date (W3CDTF): 2015-10
• Periodical title: Reproductive Sciences
• No. or year of volume/issue: 22 10
• Volume: 22
• Issue: 10
• Pages: 1272-1280
• Publication date of volume/issue (W3CDTF): 2015-10
• ISSN (Periodical Title): 19337191
• Publication (Periodical Title): Springer Science and Business Media LLC
• Subject Heading: Vascular Endothelial Growth Factor Receptor-1; Dose-Response Relationship, Drug; Drug Repositioning; Intracellular Signaling Peptides and Proteins; Neovascularization, Physiologic; Phosphodiesterase 5 Inhibitors; Pregnancy Proteins; Up-Regulation; Pre-Eclampsia; Vardenafil Dihydrochloride; Pregnancy; Case-Control Studies; Human Umbilical Vein Endothelial Cells; Humans; Angiogenesis Inducing Agents; Female; Cells, Cultured; Placenta Growth Factor
• Target Audience: 一般
• Standard No. (Other): PMID : 25736325
• DOI: 10.1177/1933719115574340
• Date Created (W3CDTF): 2015-03-04
• Rights (production): https://www.springer.com/tdm
• Related Material (URI): https://link.springer.com/content/pdf/10.1177/1933719115574340.pdf; http://journals.sagepub.com/doi/full-xml/10.1177/1933719115574340; https://link.springer.com/article/10.1177/1933719115574340/fulltext.html; http://journals.sagepub.com/doi/pdf/10.1177/1933719115574340
• Is Referenced By: Pathophysiology of preeclampsia: an angiogenic imbalance and long-lasting systemic vascular dysfunction; https://cir.nii.ac.jp/crid/1360002216791752192; Metformin attenuates lung fibrosis development via NOX4 suppression; https://cir.nii.ac.jp/crid/1360846643927729920; Potency of Tokishakuyakusan in treating preeclampsia: Drug repositioning method by in vitro screening of the Kampo library; https://cir.nii.ac.jp/crid/1360853567777727360; Preeclampsia: Maternal Systemic Vascular Disorder Caused by Generalized Endothelial Dysfunction Due to Placental Antiangiogenic Factors; https://cir.nii.ac.jp/crid/1361413119191567872
• References: Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model; https://cir.nii.ac.jp/crid/1360002217131108480; In vitro assays of angiogenesis for assessment of angiogenic and anti-angiogenic agents; https://cir.nii.ac.jp/crid/1360011143623715584; WHO analysis of causes of maternal death: a systematic review; https://cir.nii.ac.jp/crid/1360011143848854656; Preeclampsia; https://cir.nii.ac.jp/crid/1360011143886803584; Pre-eclampsia; https://cir.nii.ac.jp/crid/1360011145273919488; β-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression; https://cir.nii.ac.jp/crid/1360011145470886528; Predicting new molecular targets for known drugs; https://cir.nii.ac.jp/crid/1360011146333899264; Nicotine restores endothelial dysfunction caused by excess sFlt1 and sEng in an in vitro model of preeclamptic vascular endothelium: a possible therapeutic role of nicotinic acetylcholine receptor (nAChR) agonists for preeclampsia; https://cir.nii.ac.jp/crid/1360292618924535680; Lessons from 60 years of pharmaceutical innovation; https://cir.nii.ac.jp/crid/1360292620454028672; Sildenafil Citrate Rescues Fetal Growth in the Catechol- <i>O</i> -Methyl Transferase Knockout Mouse Model; https://cir.nii.ac.jp/crid/1360855569699382784; A Phosphodiesterase-5 Inhibitor Vardenafil Enhances Angiogenesis Through a Protein Kinase G–Dependent Hypoxia-Inducible Factor-1/Vascular Endothelial Growth Factor Pathway; https://cir.nii.ac.jp/crid/1360855569955351808; Market Failure and the Poverty of New Drugs in Maternal Health; https://cir.nii.ac.jp/crid/1360855570153340800; Tobacco and pregnancy; https://cir.nii.ac.jp/crid/1361418519040807168; Increased Nitric Oxide Synthase Activity and Expression in the Human Uterine Artery During Pregnancy; https://cir.nii.ac.jp/crid/1361418520143822208; Effects of sildenafil, a type‐5 cGMP phosphodiesterase inhibitor, and papaverine on cyclic GMP and cyclic AMP levels in the rabbit corpus cavernosum <i>in vitro</i>; https://cir.nii.ac.jp/crid/1361699994833234816; A Randomised, Double-Blinded, Placebo-Controlled Study of the Phosphodiesterase Type 5 Inhibitor Sildenafil for the Treatment of Preeclampsia; https://cir.nii.ac.jp/crid/1361981468781777792; https://cir.nii.ac.jp/crid/1362262944295267328; Enhanced Vascular Reactivity During Inhibition of Nitric Oxide Synthesis in Pregnant Rats; https://cir.nii.ac.jp/crid/1362262944668410624; The phosphodiesterase 5 inhibitor sildenafil stimulates angiogenesis through a protein kinase G/MAPK pathway; https://cir.nii.ac.jp/crid/1362262945472990080; A Repurposing Strategy Identifies Novel Synergistic Inhibitors of <i>Plasmodium falciparum</i> Heat Shock Protein 90; https://cir.nii.ac.jp/crid/1362262946100594048; Soluble Endoglin and Other Circulating Antiangiogenic Factors in Preeclampsia; https://cir.nii.ac.jp/crid/1362544419262938624; Angiogenic imbalance in the pathophysiology of preeclampsia: Newer insights; https://cir.nii.ac.jp/crid/1362825894171838592; Sildenafil citrate decreases sFlt-1 and sEng in pregnant l-NAME treated Sprague–Dawley rats; https://cir.nii.ac.jp/crid/1362825895026926208; Identification of known drugs that act as inhibitors of NF-κB signaling and their mechanism of action; https://cir.nii.ac.jp/crid/1362825895038181504; Urinary Placental Growth Factor and Risk of Preeclampsia; https://cir.nii.ac.jp/crid/1362825895580841600; Pravastatin for the Prevention of Preeclampsia in High-Risk Pregnant Women; https://cir.nii.ac.jp/crid/1362825896070158848; New uses for old drugs; https://cir.nii.ac.jp/crid/1363670318638179200; Sildenafil citrate therapy for severe early-onset intrauterine growth restriction; https://cir.nii.ac.jp/crid/1363670320712764928; Resolution of high uterine artery pulsatility index and notching following sildenafil citrate treatment in a growth‐restricted pregnancy; https://cir.nii.ac.jp/crid/1363951795745327744; Effects of a phosphodiesterase-5 (PDE5) inhibitor on endothelium-dependent relaxation of myometrial small arteries; https://cir.nii.ac.jp/crid/1363951796223773184; Circulating Angiogenic Factors and the Risk of Preeclampsia; https://cir.nii.ac.jp/crid/1364233269294023424
• Data Provider (Database): 国立情報学研究所 : CiNii Research; https://cir.nii.ac.jp/
• Original Data Provider (Database): Crossref; https://www.crossref.org; 科学研究費助成事業データベース; https://kaken.nii.ac.jp/ja

• Summary, etc.: We screened a library of 528 approved drugs to identify candidate compounds with therapeutic potential as preeclampsia treatments via their proangioge...